Positrigo Analysis: $14M Raised
What is Positrigo?
Ultra-compact brain PET system for dementia and neurology diagnostics
HQ Country
Zürich, Switzerland
Employees
11-50
Founded
2018
Funding Category
Series A
HQ Full Address
Zürich, Switzerland
Product Features & Capabilities
- NeuroLF brain PET system
- FDA and CE cleared for clinical use
- Ultra-compact design
- Functional brain imaging for dementia and neurology
Other Considerations
FDA cleared for breakthrough brain PET system; CE marked in Europe; First US outpatient neurology clinic to purchase NeuroLF; First university medical center in Germany to receive NeuroLF; iF Design Award 2025 winner; Series B funding of CHF 5.5 million; Swiss Accelerator grant from Innosuisse; Partnered with Bottneuro for clinical research collaboration; Published proof-of-concept in Journal of Imaging; Completed exploratory clinical study with BPET device; Received European Innovation Council (EIC) funding for breakthrough technology
